PFS
RXDX

Prospera Financial Services’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Prospera Financial Services’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,125
Closed -$156K – 2752
2022
Q1 		$156K Buy
+4,125
New +$163K 0.01% 958

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prospera Financial Services's RXDX Position: Q2 2022 in Review

Prospera Financial Services sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2022, closing a stake of 4,125 shares — an estimated $156K sold.

Prospera Financial Services first reported a position in RXDX in Q1 2022 and held it in 1 quarter. The position peaked at $156K in Q1 2022. 116 funds tracked by Wall St. Rank hold RXDX as of Q2 2022.

  • Prospera Financial Services reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 4,125 Prometheus Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $156K.
  • Prospera Financial Services first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Prometheus Biosciences, Inc. Common Stock position peaked at $156K in Q1 2022.
  • 116 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.